Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange Detected- Added a government-operating-status notice and a current operating status link, and - updated the revision version from v3.1.0 to v3.2.0. No other substantive content changes were detected.SummaryDifference2%

- Check24 days agoChange DetectedUpdated the page from Revision: v3.0.2 to Revision: v3.1.0, signaling a new software version.SummaryDifference0.0%

- Check39 days agoChange DetectedPage revision updated to v3.0.2 and Back to Top UI element removed.SummaryDifference0.1%

- Check47 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%

- Check54 days agoChange DetectedThe web page has been updated to include a new facility name and location, as well as specific details about a clinical trial involving pembrolizumab and cabozantinib for renal cell carcinoma. Notably, previous mentions of clear cell renal cell carcinoma and various pharmacological terms have been removed.SummaryDifference3%

- Check68 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.